ReviewFrontiers in cardiovascular medicine2025
Cancer therapy-related cardiovascular aging: mechanisms, monitoring, and intervention strategies.
Review in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neoplastic Disorders and Cardiovascular Comorbidities in Geriatric Patients: A Simple Association?Geriatrics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Significant improvements in cancer survival rates have been achieved through advancements in treatment and early diagnosis. However, non-cancer-related mortality among cancer survivors continues to rise each year. Cardiovascular diseases (CVDs) related to cancer therapy now rank as the second leading cause of death in survivors, sometimes surpassing the cancer itself. Among these, cardiovascular aging represents one of the most severe side effects, often leading to detrimental structural changes such as cardiac atrophy or fibrosis, which ultimately impair cardiac function and reduce survival. Preventing or treating cardiovascular aging has emerged as a promising strategy to mitigate Cancer Therapy-Related Cardiovascular Toxicity (CTR-CVT). This review offers a comprehensive analysis of the characteristics and mechanisms underlying cancer therapy-induced accelerated cardiovascular cellular senescence, outlines current monitoring and intervention strategies, and explores future research opportunities and challenges. Enhancing the understanding of Cancer Therapy-Related Cardiovascular Cellular Senescence and Cancer Therapy-Related Cardiovascular Aging (CTR-CVA) is crucial for optimizing cancer treatment, advancing medical research, and improving clinical practice, all of which are vital for preserving cardiac health and improving the quality of life of patients with cancers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.